
MDxHealth SA (MDXH) Stock Forecast & Price Target
MDxHealth SA (MDXH) Analyst Ratings
Bulls say
MDxHealth is well-positioned in the growing urology market, with its proprietary genomic tests improving prostate cancer diagnosis and providing actionable information. The company has a strong track record of making bolt-on acquisitions, including the recently acquired ExoDx test, and has indicated that it is evaluating further growth opportunities. Despite recent challenges with the Resolve UTI test, MDxHealth remains focused on its core cancer business and is expected to rebound and deliver strong growth in the coming years.
Bears say
MDxHealth is facing several headwinds in the near term, including a recent Q1 miss and a surprise material guidedown for 2026 due to a notice from Medicare contractor Novitas seeking a recoupment payment of ~$10M. Additionally, the company's decision to discontinue sales of its UTI test may impact its financial performance in the near future. The company also faces risks related to slower volume growth, reimbursement issues, and potential equity dilution.
This aggregate rating is based on analysts' research of MDxHealth SA and is not a guaranteed prediction by Public.com or investment advice.
MDxHealth SA (MDXH) Analyst Forecast & Price Prediction
Start investing in MDxHealth SA (MDXH)
Order type
Buy in
Order amount
Est. shares
0 shares